Turnstone Biologics’ Post

Today, we announced our financial results and shared recent business highlights for Q1 2024. Read our full press release here ==> https://lnkd.in/gb5aRHes #TSBX #Earnings #Nasdaq #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy #sandiego

May is #NationalCancerResearchMonth where we honor the important work being undertaken by researchers, advocates, clinicians, and healthcare professionals, and we are especially proud to recognize the unwavering spirit and relentless efforts of our team members and partners who devote their careers to advancing novel therapeutics in the fight against #cancer.   At Turnstone Biologics, we are resolutely committed to profoundly transforming the treatment paradigm for patients with harder-to-treat solid tumor indications where we believe we can have the greatest impact with next-generation TIL therapies that overcome the limitations of current treatment options.   Learn more about how we are working towards expanding the frontiers of TIL therapy with our differentiated “Selected TIL” technology at www.turnstonebio.com. #NCRM24 American Association for Cancer Research Moffitt Cancer Center Centre de recherche du CHUM (CRCHUM) #cancerresearch #researchanddevelopment #clinicalresearch #TSBX #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #lifesciences #clinicaltrials #CRC #colorectalcancer #headandneckcancer #uvealmelanoma #breastcancer #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

On Wednesday, May 15th, at 11:35 am PT (2:35 pm ET), our President and CEO, Dr. Sammy Farah, will present at the 2024 Bank of America Securities Health Care Conference. Tune in and learn more about why we believe we can expand the frontiers of TIL therapy into harder-to-treat solid tumor indications with critical unmet need, such as colorectal cancer, with Turnstone's next-generation “Selected TIL therapy”. The webcast and replay details of the event can be accessed at Turnstone's Events page -> https://lnkd.in/gB7hRYKK.   Members of Turnstone’s senior management will also be available for 1x1 meetings during the conference, and we look forward to seeing you there.   #TSBX #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #CRC #colorectalcancer #headandneckcancer #uvealmelanoma #breastcancer #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Tomorrow, our Chief Scientific Officer, Dr. Stewart Abbot, will present “Unveiling the Impact of Tumor-Infiltrating Lymphocytes (TILs) on Solid Tumors & the #TCR Landscape” at the 5th Annual TCR-Based Therapies for Solid Tumors Summit in #Boston. Amongst the topics to be covered are:   -Exploring the potential of "Selected TILs", Turnstone's next generation TIL therapy, as a groundbreaking avenue to combat solid tumors; -Understanding the role of TILs as prognostic indicators and their ability to infiltrate solid tumor microenvironments; -Delving into the diverse and specialized TCR repertoires present within Selected TILs.   Dr. Abbot will also be one of the expert guest speakers in a panel discussion evaluating effectiveness, indication suitability, and future modalities within the TCR therapy landscape.   Learn more about the event here => https://lnkd.in/gF2zkg8 #Leadership #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #tcrtherapy #tcells #oncology #cancertreatment #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #team #opportunities #people #biotechnology #cellandgenetherapy Hanson Wade Group

Richly deserved.   Join us in congratulating Dr. Steven Rosenberg, Chief of the Surgery Branch at the National Cancer Institute in Bethesda, Maryland, for receiving the Award for Lifetime Achievement in Cancer Research from the American Association for Cancer Research, an award which honors an individual who has made significant fundamental contributions to cancer research. Amongst his countless accomplishments, Dr. Rosenberg led the first-ever clinical trials of TIL therapy, and his studies of cell transfer immunotherapy using tumor-infiltrating lymphocytes have resulted in durable complete remissions in patients with advanced solid cancers. We are grateful for Dr. Rosenberg’s vision and his tireless determination to meaningfully advance the field and to train generations of talented investigators, all of which enables the critical work we are undertaking with our Selected TIL programs.    #AACR24 #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Yesterday, we shared recent business highlights and announced our financial results for the fourth quarter and full year 2023. Read our full press release here ==> https://lnkd.in/g_F2Z5Wm #TSBX #Earnings #Nasdaq #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy #sandiego

Did you know that colorectal cancer is the second leading cause of all U.S. cancer deaths in men and women combined? We believe the key to overcoming the challenges of #CRC and other “cold” tumors is large numbers of on-target tumor-reactive T cells, and this forms the foundation for Turnstone Biologics' Selected TIL therapy.   Learn more here about our next-generation approach to TIL therapy which is designed to create a TIL product with a significantly higher proportion of tumor-reactive T cells for patients with solid tumors who have few effective treatment options -> https://lnkd.in/g_nDH5WK   #CRCAwarenessMonth #TSBX #SelectedTIL #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #colorectalcancer #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Dr. Sammy Farah, Turnstone’s President and CEO, is in #Boston today to speak at the TD Cowen Inc. 44th Annual Healthcare Conference.   Join Sammy who, following the recent monumental approval of Amtagvi, a 1st-generation TIL therapy in advanced melanoma, will present on the development of Turnstone’s next-generation “Selected TIL therapy”, and on why we believe that our differentiated selection step, designed to create a TIL product with a significantly higher proportion of tumor-reactive T cells, is the key to addressing a broad set of solid tumor indications with critical unmet need and expanding the frontiers of TIL therapy.   The webcast and replay details of the event can be accessed at Turnstone's Events page -> https://lnkd.in/g7W5n9qd #TDCowenHealthcare #TSBX #SelectedTILs #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #colorectalcancer #headandneckcancer #uvealmelanoma #breastcancer #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

Members of Turnstone's senior management team will participate at the following investor conferences in March:   TD Cowen Inc. 44th Annual Global Health Care Conference   -Type: Presentation and one-on-one investor meetings -Speaker: Sammy Farah, M.B.A., Ph.D., President and CEO -Date: Wednesday, March 6, 2024 -Location: Boston, MA   Leerink Partners Global Biopharma Conference 2024   -Type: One-on-one investor meetings -Date: Wednesday, March 13, 2024 -Location: Miami, FL   Should you plan to attend, do get in touch with the team to connect, and for further details on our participation, please read our press release here ==> https://lnkd.in/djTdqpiv   #TDCowenHealthCare #LeerinkPartners #Conference #TSBX #SelectedTIL #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy